TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7538514

Group type: EXPERIMENTAL
Intervention: Controlled-release hydromorphone (CR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate-release hydromorphone (IR)
Number of subjects: 18
Study: 1689988

Group type: EXPERIMENTAL
Intervention: KRN 8601 (rhG-CSF) at a dose of 75 micrograms/body administered subcutaneously for 14 days after the second cycle of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 456734

Group type: EXPERIMENTAL
Intervention: Trimebutine (Mebutin), 200 mg three times daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trimebutine (Mebutin)
Number of subjects: 20
Study: 30714205

Group type: EXPERIMENTAL
Intervention: Wi‐Fi users (n=174)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Wi‐Fi nonusers (n=138)
Number of subjects: 312
Study: 28858567

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-Ed (web-based OSA education)
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-TM (CPAP telemonitoring with automated feedback)
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-both (Tel-Ed and Tel-TM)
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-Ed
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-TM
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Tel-both
Number of subjects: 1455
Study: 27547895

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of a review lecture, electronic information card, and monthly individual physician feedback via email.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Educational intervention.
Number of subjects: 66
Study: 24012064

Group type: EXPERIMENTAL
Intervention: Cigarette packages with 'natural' descriptors
Number of subjects: 7647

Group type: EXPERIMENTAL
Intervention: Cigarette packages with filter references
Number of subjects: 7647

Group type: COMPARATOR
Intervention: Contraband cigarettes
Number of subjects: 7647
Study: 22507979

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly subcutaneous injection
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Liver fat content assessment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Liver needle biopsy
Number of subjects: 33
Study: 20518185

Group type: EXPERIMENTAL
Intervention: Acupoints compatibility rules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupoints compatibility rules based on experimental researches
Number of subjects: 0
Study: 18030236

Group type: EXPERIMENTAL
Intervention: Light-protected (LP) TPN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light-exposed (LE) TPN
Number of subjects: 0
Study: 16054553

Group type: EXPERIMENTAL
Intervention: Nut diet (30 g/d nuts)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cereal diet (Canola oil enriched cereal)
Number of subjects: 28
Study: 12670859

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 86
Study: 11192563

Group type: EXPERIMENTAL
Intervention: Multidisciplinary vocational rehabilitation programme with additional work training and case management
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation programme
Number of subjects: 24
Study: 8991314

Group type: EXPERIMENTAL
Intervention: Therapists classified as more effective based on patient outcomes in active treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderately and less effective therapists.
Number of subjects: 0
Study: 1460207

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent nasal spray)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0
Study: 6567715

Group type: EXPERIMENTAL
Intervention: Classroom instruction
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Media only
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study: 31441025

Group type: EXPERIMENTAL
Intervention: QuikClot Combat Gauze (QCG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Celox Rapid (CR)
Number of subjects: 21
Study: 30278407

Group type: EXPERIMENTAL
Intervention: P(v-a)CO2/C(a-v)O2-targeted therapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: ScvO2-targeted therapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 228
Study: 26334128

Group type: EXPERIMENTAL
Intervention: Massage (30-min massage after exercise)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal passive recovery)
Number of subjects: 30
Study: 24595511

Group type: EXPERIMENTAL
Intervention: MBCT + depression relapse active monitoring (DRAM)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (DRAM alone)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MBCT + DRAM
Number of subjects: 203
Study: 22459549

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Lasmiditan 400 mg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 19864449

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study: 17572467

Group type: EXPERIMENTAL
Intervention: Stereoscopic three-dimensionality presentation of faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synoptic presentation of faces
Number of subjects: 0
Study: 16239885

Group type: EXPERIMENTAL
Intervention: 23.4% sodium chloride solution
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 13
Study: 11929393

Group type: EXPERIMENTAL
Intervention: ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: ABT-229
Number of subjects: 324
Study: 10048009

Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (Trusopt)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 8062495

Group type: EXPERIMENTAL
Intervention: Combination product of trimethoprim (15 mg/kg/day) and sulfamethoxazole (75 mg/kg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients who discontinued therapy due to toxicity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with major liver toxicity
Number of subjects: 15
Study: 3232130

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d. for 21 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30961558

Group type: EXPERIMENTAL
Intervention: Educational intervention (Cinema Voice)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 29582623

Group type: EXPERIMENTAL
Intervention: Intramyocardial autologous bone marrow mononuclear stem cells (BMMNC) grafting combined with CABG
Number of subjects: 20

Group type: COMPARATOR
Intervention: CABG only (Control)
Number of subjects: 20
Study: 26445857

Group type: EXPERIMENTAL
Intervention: Deep chamfer preparation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Feather edge preparation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 200
Study: 24756814

Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy (EBRT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Surgery alone (LSS)
Number of subjects: 141
Study: 21850496

Group type: EXPERIMENTAL
Intervention: Blood orange juice (1 L/day for 4 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blond orange juice (1 L/day for 4 weeks)
Number of subjects: 18
Study: 20021703

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (5 g, twice daily for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17612637

Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 99

Group type: COMPARATOR
Intervention: Patients without CAD
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 99
Study: 16096435

Group type: EXPERIMENTAL
Intervention: 3 cycles of epidoxorubicin/docetaxel
Number of subjects: 45
Study: 11872201

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily) and placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (66 mg daily) and placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (66 mg daily) and folic acid (5 mg daily)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Two placebos
Number of subjects: 211
Study: 9788828

Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril (E) 20 mg/d
Number of subjects: 16
Study: 7714227

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2806234

Group type: COMPARATOR
Intervention: CONTROL (light work clothing)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SCBA (light work clothing with open circuit self‐contained breathing apparatus)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FF (firefighter's turnout gear with SCBA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHEM (chemical protective clothing with SCBA)
Number of subjects: 9
Study: 792739

Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 68

Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 68
Study: 7340881

Group type: EXPERIMENTAL
Intervention: Frusemide (0.25 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Piretanide (0.1 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Gentamicin alone (1 mg/kg)
Number of subjects: 6
Study: 30848803

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of less than 120 mm Hg (intervention treatment)
Number of subjects: 466
Study: 28017248

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%–1% solution, 2 drops to each eye
Number of subjects: 7
Study: 25365779

Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (MI)
Number of subjects: 129
Study: 25216556

Group type: EXPERIMENTAL
Intervention: High frequency rTMS over the right inferior frontal gyrus (IFG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vertex (control stimulation site)
Number of subjects: 10
Study: 22690882

Group type: EXPERIMENTAL
Intervention: Web-based tailored cessation advice report
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Web-based non-tailored cessation advice report
Number of subjects: 1758
Study: 20004966

Group type: EXPERIMENTAL
Intervention: CAF plus tamoxifen (CAFT or CAF-T)
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: CAF-T
Number of subjects: 1477
Study: 17562231

Group type: EXPERIMENTAL
Intervention: Vinorelbine (25-30 mg/m² on days 1 and 8 every 3 weeks)
Number of subjects: 39
Study: 15160563

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 0
Study: 11219633

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate, administered bilaterally for 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 12
Study: 9728839

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine alone (Group B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine with 75 microg of clonidine (Group BC)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine with 75 microg of clonidine and 12.5 microg of fentanyl (Group BCF)
Number of subjects: 78
Study: 8054251

Group type: EXPERIMENTAL
Intervention: Ketoprofen (3 mg kg‐1 day‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (3 mg kg‐1 day‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg day‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-NSAID control (paracetamol/acetaminophen)
Number of subjects: 10
Study: 3133575

Group type: EXPERIMENTAL
Intervention: Systemic natural alpha interferon (IFN) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30296709

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (cycling at 40% of maximum oxygen uptake for 20 min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 19
Study: 28538774

Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure (BiPAP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study: 26122012

Group type: COMPARATOR
Intervention: Cord blood 25(OH)D 25‐50 nmol/L at delivery
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Cord blood 25(OH)D >50 nmol/L at delivery
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Cord blood 25(OH)D <25 nmol/L at delivery
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: DHA group (specific intervention not detailed)
Number of subjects: 1040
Study: 23458374

Group type: EXPERIMENTAL
Intervention: Antismoking media literacy program (five 1-hour lessons)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Creative writing control program
Number of subjects: 38
Study: 21930067

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (supervised physical therapy training for 6 weeks + unsupervised maintenance program for 6 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 19371843

Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhalational gas requirement
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative morphine equivalence requirements
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subjective pain using visual analog scale
Number of subjects: 17
Study: 16416228

Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol mixture (25 g fructose and 5 g sorbitol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Glucose (30 g)
Number of subjects: 11
Study: 15580199

Group type: EXPERIMENTAL
Intervention: Combined telephone asthma coaching and monetary incentive
Number of subjects: 527

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 527
Study: 10583701

Group type: COMPARATOR
Intervention: Generic digoxin preparation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lanoxin
Number of subjects: 14
Study: 8975569

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline, propranolol, and phenazepam for causalgic form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of carbamazepine, propranolol, and phenazepam for neuralgic form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tizanidine monotherapy for spastic form
Number of subjects: 0
Study: 1829306

Group type: EXPERIMENTAL
Intervention: 10 micrograms Recombivax‐HB (Merck Sharpe & Dohme Ltd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 micrograms Engerix‐B (Smith Kline Biologicals)
Number of subjects: 0
Study: 6348635

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Oral vitamin E administered early (<12 hours of age)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Oral vitamin E administered after 39 hours of age (mean age 167.5 hours)
Number of subjects: 174

Group type: COMPARATOR
Intervention: No vitamin E
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Early parenteral and oral vitamin E
Number of subjects: 174
Study: 31097081

Group type: EXPERIMENTAL
Intervention: Pemetrexed (Pem)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Bevacizumab (Pem + Bev)
Number of subjects: 40
Study: 30355096

Group type: EXPERIMENTAL
Intervention: 4-factor prothrombin complex concentrate and vitamin K infusion followed by intravenous thrombolysis (IVT)
Number of subjects: 26
Study: 27400075

Group type: EXPERIMENTAL
Intervention: Tecnis Multifocal Toric IOL
Number of subjects: 30
Study: 24615354

Group type: EXPERIMENTAL
Intervention: Light-intensity leisure-time physical activity (LTPA)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity leisure-time physical activity (LTPA)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Predictors of light-intensity LTPA
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Predictors of moderate-to-vigorous-intensity LTPA
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Factors encouraging LTPA
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Barriers to LTPA
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Predictors for maintaining LTPA during pregnancy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Common barriers to LTPA
Number of subjects: 399
Study: 21775117

Group type: EXPERIMENTAL
Intervention: Diet plus a medical food containing soy protein and plant sterols (n=20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diet only (n=15)
Number of subjects: 35
Study: 21093036

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (previous treatment alone)
Number of subjects: 106
Study: 18533779

Group type: COMPARATOR
Intervention: Coronally positioned flap plus acellular dermal matrix (ADM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coronally positioned tunnel technique plus acellular dermal matrix (ADM)
Number of subjects: 24
Study: 15672113

Group type: EXPERIMENTAL
Intervention: Yogurt (1100 mg Ca/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (400‐500 mg Ca/day)
Number of subjects: 34
Study: 12804845

Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC (IL-2-supplemented trivalent liposomal influenza vaccine)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard trivalent split virion vaccine (control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC
Number of subjects: 81

Group type: COMPARATOR
Intervention: INFLUSOME-VAC and Standard vaccine
Number of subjects: 81
Study: 10372695

Group type: EXPERIMENTAL
Intervention: Testosterone patch
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108
Study: 10829968

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) latex agglutination test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) CRP test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF CRP test
Number of subjects: 0
Study: 1866542

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime plus vancomycin
Number of subjects: 0
Study: 6347748

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31282169

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (3 sessions per week)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 129
Study: 28017756

Group type: EXPERIMENTAL
Intervention: Stand-alone intervertebral spacer with integrated screw fixation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Anterior cervical plate and spacer construct
Number of subjects: 54
Study: 26966919

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 1137
Study: 24666729

Group type: EXPERIMENTAL
Intervention: Continuous BFR
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intermittent BFR
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (exercise without BFR)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups (after 5-week training)
Number of subjects: 43
Study: 21537928

Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 10

Group type: COMPARATOR
Intervention: CONT
Number of subjects: 10
Study: 20398248

Group type: EXPERIMENTAL
Intervention: Cranberry powder standardized for proanthocyanidin content (72 mg of PAC per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18590519

Group type: COMPARATOR
Intervention: Abrupt strategy (olanzapine discontinued at risperidone initiation)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Gradual 1 strategy (olanzapine at 50% entry dose for 1 week after risperidone initiation)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gradual 2 strategy (olanzapine at 100% entry dose for 1 week, then at 50% in the second week)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: All strategies (switching from olanzapine to risperidone)
Number of subjects: 123
Study: 15971073

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy at 1.5 mg kg(‐1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy at 3.0 mg kg(‐1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy (both doses)
Number of subjects: 66
Study: 12452021

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy combined with total body irradiation (TBI) or total lymph node irradiation (TLI)/subtotal lymph node irradiation (STLI)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Complementary irradiation in the primary sites after transplantation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall treatment (HDT combined with ASCT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transplant-related toxicity
Number of subjects: 11
Study: 10609211

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 64